Newsroom | 49835 results

Sorted by: Latest
Clinical Trials
-

Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China

SHANGHAI & BOSTON--(BUSINESS WIRE)--Eccogene Announces Positive Topline Results from Phase 1b Trial in China of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist...
-

Nucleus Biologics Launches Krakatoa® K500: A Pod-Based, On-Demand Media and Buffer Manufacturing System Transforming Scale Bioproduction

SAN DIEGO--(BUSINESS WIRE)--Nucleus Biologics launched the Krakatoa® K500, a pod-based, on-demand manufacturing system that produces 35–500L of media and buffers at point of use....
-

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026...
-

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape. Titled ‘Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress’, the webinar will explore re...
-

Experic Announces the Appointment of Matthew Mollan, Ph.D. as Chief Executive Officer

CRANBURY, N.J.--(BUSINESS WIRE)--Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, today announced the appointment of Matthew Mollan, Ph.D., as Chief Executive Officer. Dr. Mollan joins Experic after more than three decades in leadership positions with pharmaceutical development and manufacturing organizations. His experience includes a strong track record of operational excellence, P&L le...
-

OrsoBio Announces Positive Topline Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and Metabolic Liver Disease

MENLO PARK, Calif.--(BUSINESS WIRE)--Phase 2a trial of OrsoBio's TLC-2716 in SHTG and MASLD saw clinically meaningful reductions in triglycerides, remnant cholesterol, and liver fat....
-

CinRx Appoints Rez Halse, PhD, as President to Lead Its Portfolio of Clinical-Stage Development Companies and Accelerate Growth

CINCINNATI--(BUSINESS WIRE)--CinRx Pharma Appoints Rez Halse as President...
-

IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and the Duke Clinical Research Institute (DCRI), one of the world’s largest academic clinical research organizations with extensive experience designing and operationally executing large, complex multi-center clinical trials, are pleased to announce their new collaboration to enha...
-

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domai...
-

Study Shows AccurKardia’s AI-Enabled ECG Can Detect Aortic Stenosis Years Before Valve Replacement and Improve Mortality Risk Prediction

NEW YORK--(BUSINESS WIRE)--AccurKardia, an innovator in ECG-based diagnostics technology, today announced results from a new study demonstrating that its AI-enabled ECG technology, AK-AVS™, can detect aortic stenosis years before patients require valve replacement and improve prediction of clinical outcomes. The study, “Validation and Longitudinal Trajectory Analysis of an AI-Based ECG Model for Aortic Stenosis: From Community Screening to Pre-TAVR Risk Stratification,” was led by principal inv...